Praxis Medica
Sign in
Issue image

More articles from Volume 53, Issue 2, 2025

NOVI IZAZOVI U PREVENCIJI KARDIOVASKULARNIH BOLESTI

METABOLIČKI SINDNROM - UTICAJ NA REPRODUKTIVNI STATUS ŽENE

ISTORIJSKI RAZVOJ SRPSKOG LEKARSKOG DRUŠTVA OD 1872. DO 2025. GODINE

KARCINOM PLUĆA-SAVREMENI IZAZOVI U ISPITIVANJU I LEČENJU

SRČANA INSUFICIJENCIJA – SAVREMENI PRISTUP

KARCINOM PLUĆA-SAVREMENI IZAZOVI U ISPITIVANJU I LEČENJU

Maja Ercegovac ,
Maja Ercegovac
View authors publications

Search this author on:

PubMed | Google Scholar
Slaviša Baščarević ,
Slaviša Baščarević
View authors publications

Search this author on:

PubMed | Google Scholar
Dragana Marić ,
Dragana Marić
View authors publications

Search this author on:

PubMed | Google Scholar
Marko Popović
Marko Popović
View authors publications

Search this author on:

PubMed | Google Scholar

Published: 30.06.2025.

Volume 53, Issue 2 (2025)

pp. 24-26;

https://doi.org/10.70949/pramed202502000E

Abstract

 Karcinom pluća je najčešći karcinom u odnosu na incidencu i vodeći uzrok smrtnosti od malignih bolesti. Visoka incidenca  i mortalitet su stalni motiv
 za istraživanja na polju poboljšanja ranog otkrivanja potencijalnog karcinoma, unapređenja složenih metoda dijagnostike i lečenja bolesnika sa
 karcinomom pluća.
 Rano otkrivanje karcinoma primenom niskodozne kompjuterizovane tomografije grudnog koša je prema rezultatima nekih studija ( National Lung
 Screening Trial) smanjilo mortalitet za 20%. Implementacija programa skrininga zahteva poznavanje osnovih principa i protokola rada, tumačenja
 rezultata i postupaka na osnovu dobijenih nalaza.
 Otkrivanje tumora u ranoj fazi omogućava i veći procenat bolesnika kod kojih je moguće hirurško lečenje kao i primena minimalno invazivne hirurgije
 (VATS-video-asistirana torakoskopska hirurgija) i ograničenih sublobarnih resekcija.
 Lokalna kontrola bolesti se može postići i primenom  stereotaksične radioterapije tela (SBRT), ciljano usmerene na tumor sa minimalnim efektima na
 okolni plućni parenhim. SBRT je posebno značajna kao metoda lokalne terapije karcinoma kod bolesnika koji nisu kandidati ili ne prihvataju hirurško
 lečenje.
 Značajne promene  na planu sistemskog lečenja nastale suuvođenjem u kliničku praksu molekularne (ciljane) terapije i imunoterapije.
 Savremenе metode otkrivanja, ispitivanja, hirurškog lečenja, radioterapije i sistemskog lečenja  zahtevaju multidisciplinarni timski pristup lečenju
 bolesnika sa karcinomom pluća.
 Ključne reči: karcinom pluća, skrining, radioterapija, ciljana terapija

Keywords

karcinom pluća,

skrining,

radioterapija,

ciljana terapija

References

1.
Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, B G, et al. The National Lung Screening Trial:overview and study design. Radiology. 2011;258:243–53.
2.
Association AL. Providing Guidance on Lung Cancer Screening to Patients and Physicians.http://www.lung.org/lung-health-and-disease/lung-disease-lookup/lung-cancer/diagnosing-and-treatment/lung-cancer-screening.
3.
Tammemagi MC. Application of risk prediction models to lung cancer screening.A review. J Thorac Imaging. 2015;30:88–100.
4.
Pedersen JH, Rzyman W, Veronesi G, D’Amico TA, Schil P, Molins L, et al. Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe. Eur J Cardiothorac Surg. 2017;51:411–20.
5.
Rocco G, Allen M, Altorki NK, Asamura H, Blum MG, F D, et al. Clinical statement on the role of the surgeon and surgical issues relating to computed tomography screening programs for lung cancer. Ann Thorac Surg. 2013;96:357–60.
6.
Gossot D. Lobar or sublobar resections for early-stage lung cancer:at the crossroads. Eur J Cardiothorac Surg. 2021;60:1295–6.
7.
Kamel M, Lee B, Harrison S, Port J, Pua B, N A, et al. Do the surgical results in the National Lung Screening Trial reflect modern thoracic surgical practice? J Thorac Cardiovasc Surg. 2019;157:2038–46.
8.
Xiao F, Yu Q, Zhang Z, Liu D, Guo Y, C L, et al. Novel perspective to evaluate the safety of segmentectomy: clinical significance of lobar and segmental lymph node metastasis in cT1N0M0 lung adenocarcinoma. Eur J Cardiothorac Surg. 2018;53:228–34.
9.
Weder W, Moghanaki D, Stiles B, Siva S, Rocco G. The great debate flashes: surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer. Eur J Cardiothorac Surg. 2018;53:295–305.
10.
Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2022;62(3).
11.
Sanmamed MF, Eugen-SantamariaI. Schalper KA.Overview of Lung Cancer Immunotherapy. Cancer J. 2020;26(6):473–84.
12.
Araghi M, Mannami R, Maleki AH, Hamidi A, Rostami S, Safar SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update overview.

Citation

Copyright

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by
DOAJ
Google Scholar
ERIHPLUS
MIAR I
Crossref